Can the etonogestrel sub‑dermal implant (Implanon) be used off‑label for endometrial protection in a post‑menopausal woman receiving estrogen‑only hormone replacement therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Implanon Be Used Off-Label for Endometrial Protection in HRT?

No, the etonogestrel subdermal implant (Implanon) should not be used for endometrial protection in postmenopausal women receiving estrogen-only HRT. While it has progestogenic effects on the endometrium, there is insufficient evidence supporting its efficacy for this specific indication, and alternative proven options exist.

Why Implanon Is Not Recommended

The 2015 Endocrine Society guidelines explicitly address progestogen options for endometrial protection in HRT but do not include the etonogestrel implant 1. Instead, the guidelines recommend:

  • Concurrent progestogen therapy for at least 12 days per month to reduce endometrial hyperplasia and cancer risk in women with a uterus receiving estrogen therapy 1
  • Continuous combined regimens or sequential regimens with established safety profiles 1

The Only Off-Label Implantable Option With Evidence

The levonorgestrel intrauterine device (LNG-IUD) is the only implantable progestogen delivery system mentioned in guidelines for endometrial protection, and it "appears effective at minimizing hyperplasia and endometrial cancer risk, especially in obese women" 1. This is widely used off-label in the United States for this indication 1.

Why the Evidence Doesn't Support Etonogestrel Implants for HRT

The critical difference lies in local vs. systemic progestogen delivery:

  • A 1995 comparative study demonstrated that subdermal levonorgestrel implants provided inadequate endometrial suppression compared to intrauterine delivery, despite similar serum hormone levels 2
  • The subdermal implant group showed "weak or absent progestin effect" on endometrial histology, while the IUD group showed "uniform atrophy" 2
  • Bleeding control was significantly worse with subdermal administration (8 days spotting + 3.4 days bleeding vs. 0.9 days spotting + 0 days bleeding) 2

While etonogestrel implants do affect the endometrium in contraceptive users 3 and have even shown regression of endometrial intraepithelial neoplasia in one case report 4, these effects occur in premenopausal women without exogenous estrogen exposure—a fundamentally different scenario than postmenopausal HRT.

The Clinical Problem

In postmenopausal HRT, you're adding systemic estrogen that stimulates endometrial proliferation. The progestogen must provide sufficient endometrial opposition to prevent hyperplasia. The subdermal etonogestrel implant:

  • Delivers progestogen systemically rather than locally to the endometrium
  • Has not been studied in RCTs for endometrial protection during estrogen HRT
  • Showed inadequate endometrial suppression in the one comparative study available 2

What to Use Instead

For women requiring endometrial protection during estrogen HRT:

  1. First-line: Oral progestogens (micronized progesterone, MPA, dydrogesterone, NETA) in continuous or sequential regimens 1, 5
  2. Off-label alternative: LNG-IUD, particularly in obese women 1
  3. For low-dose vaginal estrogen only: No progestogen needed 1

Critical Caveat

Do not confuse contraceptive efficacy with endometrial protection during HRT. The etonogestrel implant is highly effective for contraception 6 but this does not translate to adequate endometrial protection against estrogen-induced hyperplasia in postmenopausal women receiving systemic HRT.

References

Guideline

treatment of symptoms of the menopause: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2015

Research

Endometrial effects of etonogestrel (Implanon) contraceptive implant.

Current opinion in obstetrics & gynecology, 2001

Research

Progestogens for endometrial protection in combined menopausal hormone therapy: A systematic review.

Best practice & research. Clinical endocrinology & metabolism, 2024

Research

Use of etonogestrel implant beyond approved duration: prolonged contraceptive effectiveness.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.